Article
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
British journal of cancer - 31 Mar 2015
Xu C-F, Johnson T, Garcia-Donas J, Choueiri T K, Sternberg C N, Davis I D, Bing N, Deen K C, Xue Z, McCann L, Esteban E, Whittaker J C, Spraggs C F, Rodríguez-Antona C, Pandite L N, Motzer R J
Abstract excerpt
BACKGROUND: We evaluated germline single nucleotide polymorphisms (SNPs) for association with overall survival (OS) in pazopanib- or sunitinib-treated patients with advanced renal cell carcinoma (aRCC). METHODS: The discovery analysis tested 27 SNPs within 13 genes from a phase III pazopanib trial (N=241, study 1). Suggestive associations were then pursued in two independent datasets: a phase III trial (COMPARZ)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
